• The U.S. FDA is proposing issuing an order that would remove the oral decongestant phenylephrine from many over-the-counter cough and cold medicines as a review has found the drug ineffective.
• The agency said that a comprehensive evaluation examined data from decades ago used to support oral phenylephrine's initial approval as well as newer data. Other formulations of phenylephrine are not impacted.
• Oral phenylephrine is found in many popular OTC cough and cold remedies including Kenvue's (NYSE:KVUE) Sudafed, Procter & Gamble's (PG) DayQuil and NyQuil, and Haleon's (NYSE:HLN) Robitussin and Triaminic.
• The FDA's proposed order is not a surprise considering an advisory committee in September 2023 voted that oral phenylephrine lacks effectiveness.
• The following month, CVS Health (CVS) pulled products containing oral phenylephrine from its shelves.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。